Paul Hastings Advises Ligand Pharmaceuticals on Its $700 Million Convertible Senior Notes Offering

Paul Hastings LLP advised Ligand Pharmaceuticals Incorporated (Nasdaq: LGND), a biopharmaceutical company enabling scientific advancement through supporting the clinical development of high-value medicines, in connection with its private placement of $700 million aggregate principal amount of 0.0% convertible senior notes due 2031. The offering closed on June 25, 2026.Securities & Capital Markets partner Brandon Bortner and of counsel Ryan Brewer led the Paul Hastings team, which also included partners Jaime Madell and Daniel Nicholas and associates Greg Drozdzal and Gaby Jassir. Public Company Advisory partners Brad Bondi and Sean Donahue advised on governance matters.More details can be found here.About Paul HastingsWith widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations. For more information, visit Professionals: Brandon J. Bortner Ryan S. Brewer Jaime Madell Daniel Nicholas Greg Drozdzal Gaby Jassir Brad Bondi Sean Donahue